Aurinia Pharmaceuticals (AUPH) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aurinia Pharmaceuticals applauds the American College of Rheumatology’s 2024 guidelines for lupus nephritis treatment, which recommend using their FDA-approved drug LUPKYNIS as part of a triple immunosuppressive therapy. The guidelines emphasize reducing steroid use and achieving specific proteinuria targets, highlighting the drug’s effectiveness demonstrated in clinical trials.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.